Summary: The role of CD80/CD86 and CTLA-4 in the pathogenesis of systemic lupus erythematosus and their clinical significance was investigated. By using RT-PCR technique, the expression of CD80/CD86 and CTLA-4 mRNA in...Summary: The role of CD80/CD86 and CTLA-4 in the pathogenesis of systemic lupus erythematosus and their clinical significance was investigated. By using RT-PCR technique, the expression of CD80/CD86 and CTLA-4 mRNA in peripheral blood mononuclear cells (PBMC) were semiquantitatively detected in 32 patients with active SLE. The results showed that the percentage of positive CD86 expression in active SLE was increased significantly as compared with normal controls (90.63 % vs 60.00 %, P<0.01). The mean level of CD86 mRNA expression in active SLE group was markedly higher than in the normal controls (0.6410+0.0174 vs 0.4510+0.0402, P<0.001). Compared with normal controls, the percentage of positive CTLA-4 expression and the mean level of CTLA-4 mRNA expression in active SLE group were both increased significantly (both P<0.01). There was no statistical differences in positive rate of CD80 and the average level of CD80 mRNA between the two groups (both P>0.05). It was concluded that the aberrant expression of CD86 and CTLA-4 might play an important role in the activity and development of SLE.展开更多
Objective:To determine expressions of HLA class I and CD80 in humanepithelial ovarian carcinomas(EOC) and the clinical significance.Methods:Expression of HLA class I was detected by immunohistochemical technique. Expr...Objective:To determine expressions of HLA class I and CD80 in humanepithelial ovarian carcinomas(EOC) and the clinical significance.Methods:Expression of HLA class I was detected by immunohistochemical technique. Expression of CD80 mRNA was examined by reverse transcriptions-polymerase chain reaction(RT-PCR).Results:The positive rate of HLA classⅠ was 59.09%.CD80 mRNA was expressed on 9.09% of all 44 EOC tissues.HLA classⅠ expression rate in stage Ⅲ-Ⅳ was lower than that in stage Ⅰ-Ⅱ;in tumors of node-positive patients was lower than that of node-negative patients(P<0.05).In patiens with tumors expressing HLA class Ⅰ antigens,recurrence rate was lower than that in patients with tumors deficient in HLA class Ⅰ(P<0.01).In four patients with tumors expressing CD80 mRNA,recurrence did not occur,in contrast to patients with tumors lacking CD80 mRNA,in whom tumor relapse rate was 57.5%(P<0.05).Relapse ratein tumors deficient both HLA class Ⅰ and CD80 was significantly higher than that of tumors coexpression the two molecules.Conclusions:EOC cells may escapefrom the immune surveillance of the host through downregulating expressions ofHLA class Ⅰ and CD80.Evaluation of expressions of these surface immunoregulatory molecules may be helpful for judging prognoses of EOC patients and guiding immunotherapy.展开更多
文摘Summary: The role of CD80/CD86 and CTLA-4 in the pathogenesis of systemic lupus erythematosus and their clinical significance was investigated. By using RT-PCR technique, the expression of CD80/CD86 and CTLA-4 mRNA in peripheral blood mononuclear cells (PBMC) were semiquantitatively detected in 32 patients with active SLE. The results showed that the percentage of positive CD86 expression in active SLE was increased significantly as compared with normal controls (90.63 % vs 60.00 %, P<0.01). The mean level of CD86 mRNA expression in active SLE group was markedly higher than in the normal controls (0.6410+0.0174 vs 0.4510+0.0402, P<0.001). Compared with normal controls, the percentage of positive CTLA-4 expression and the mean level of CTLA-4 mRNA expression in active SLE group were both increased significantly (both P<0.01). There was no statistical differences in positive rate of CD80 and the average level of CD80 mRNA between the two groups (both P>0.05). It was concluded that the aberrant expression of CD86 and CTLA-4 might play an important role in the activity and development of SLE.
文摘Objective:To determine expressions of HLA class I and CD80 in humanepithelial ovarian carcinomas(EOC) and the clinical significance.Methods:Expression of HLA class I was detected by immunohistochemical technique. Expression of CD80 mRNA was examined by reverse transcriptions-polymerase chain reaction(RT-PCR).Results:The positive rate of HLA classⅠ was 59.09%.CD80 mRNA was expressed on 9.09% of all 44 EOC tissues.HLA classⅠ expression rate in stage Ⅲ-Ⅳ was lower than that in stage Ⅰ-Ⅱ;in tumors of node-positive patients was lower than that of node-negative patients(P<0.05).In patiens with tumors expressing HLA class Ⅰ antigens,recurrence rate was lower than that in patients with tumors deficient in HLA class Ⅰ(P<0.01).In four patients with tumors expressing CD80 mRNA,recurrence did not occur,in contrast to patients with tumors lacking CD80 mRNA,in whom tumor relapse rate was 57.5%(P<0.05).Relapse ratein tumors deficient both HLA class Ⅰ and CD80 was significantly higher than that of tumors coexpression the two molecules.Conclusions:EOC cells may escapefrom the immune surveillance of the host through downregulating expressions ofHLA class Ⅰ and CD80.Evaluation of expressions of these surface immunoregulatory molecules may be helpful for judging prognoses of EOC patients and guiding immunotherapy.
